This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: February 4, 2010
Last updated: August 24, 2016
Last verified: August 2016
The purpose of this study is to determine the maximum tolerated dose of veliparib (ABT-888)and to establish the recommended Phase 2 dose of veliparib (ABT-888) when administered in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.

Condition Intervention Phase
Advanced Solid Tumors Drug: veliparib (ABT-888) Drug: carboplatin Drug: gemcitabine Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Veliparib in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Primary Outcome Measures:
  • Determine the maximum tolerated dose and recommended Phase 2 dose [ Time Frame: ABT-888 will be dose escalated until the largest dose is reached based on the probability of dose, limiting toxicities is based per continual reassessment method (CRM). ]

Secondary Outcome Measures:
  • Pharmacokinetics Area Under the Curve (AUC) [ Time Frame: Timepoints: 30 and 45 minutes, 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,6,6.5, 7 and 8 hours past dose ]
  • Safety assessment: Electrocardiogram [ Time Frame: Screening, Day 8 of each Cycle of drug and Final Visit ]
  • Safety assessment: Clinical Laboratory Tests [ Time Frame: Screening, Day 1 and Day 8 of each cycle, Final Visit and 30 Day Follow-up Visit ]
    Hematology and Chemistry

  • Physical exam including vital signs [ Time Frame: Screening, Cycle 1 Day 8, Day 1 of all cycles starting with Cycle2, Final Visit and 30 Day Follow-up Visit ]
    Physical exam including blood pressure, pulse and temperature

  • Safety assessment: Adverse event assessments [ Time Frame: All study visits ]
    Collect all adverse events at each visit

  • Tumor assessment [ Time Frame: Screening, every nine weeks and Final Visit ]
    Computerized tomography (CT) scan of chest, abdomen and pelvis to assess tumor burden

Enrollment: 79
Study Start Date: January 2010
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: veliparib (ABT-888)
Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
Drug: carboplatin
Carboplatin will be dosed on Day 1 of each cycle, intravenously.
Drug: gemcitabine
Dosing on Days 1 and 8 of each Cycle, intravenously.
Other Name: Gemzar


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed solid tumors that are metastatic or unrespectable for which carboplatin/gemcitabine is a treatment option.
  • Eastern Cooperative Group performance score of 0 to 2.
  • Adequate hematologic, hepatic and renal function
  • Subject has received up to 2 DNA damaging or cytotoxic regimens in the past five years

Exclusion Criteria:

  • Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within 28 days prior to study administration.
  • Subjects with known history of brain metastases and primary CNS tumors.
  • Hypersensitivity reactions to platinum compounds or gemcitabine.
  • Clinically significant and uncontrolled major medical conditions
  • Active malignancy within the past 5 years except for any cancer in situ cured or non-melanoma carcinoma of the skin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01063816

United States, California
Site Reference ID/Investigator# 23283
Duarte, California, United States, 91010
Site Reference ID/Investigator# 27743
Duarte, California, United States, 91010
United States, Illinois
Site Reference ID/Investigator# 23284
Chicago, Illinois, United States, 60637
United States, New York
Site Reference ID/Investigator# 23282
New York, New York, United States, 10065
United States, Pennsylvania
Site Reference ID/Investigator# 23286
Philadelphia, Pennsylvania, United States, 19111
United States, Washington
Site Reference ID/Investigator# 23285
Seattle, Washington, United States, 98109-1023
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Mark D McKee, MD AbbVie
  More Information

Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01063816     History of Changes
Other Study ID Numbers: M10-758
Study First Received: February 4, 2010
Last Updated: August 24, 2016

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):
PARP Inhibitors

Additional relevant MeSH terms:
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Poly(ADP-ribose) Polymerase Inhibitors processed this record on August 16, 2017